Table 3 Association of tumor GFRα1, GFRα3 and SDC3 protein expression with clinicopathologic parameters of patients with mammary carcinoma
GFRα1 expression (n (%)) | GFRα3 expression (n (%)) | SDC3 expression (n (%)) | |||||
|---|---|---|---|---|---|---|---|
Parameter | n | protein | P | protein | P | protein | P |
Age (years) | |||||||
≤ 35 | 16 | 9 (56.3) | 0.249 | 9 (56.3) | 0.078 | 5 (31.3) | 0.768 |
35-55 | 92 | 34 (37.0) | 26 (28.3) | 24 (26.1) | |||
> 55 | 51 | 17 (33.3) | 15 (29.4) | 16 (31.4) | |||
Tumor size (cm) | |||||||
≤ 2 | 13 | 6 (46.2) | 0.135 | 4 (30.8) | 0.37 | 5 (38.5) | 0.555 |
2 ~ 5 | 115 | 38 (33.0) | 33 (28.7) | 30 (26.1) | |||
> 5 | 31 | 16 (51.6) | 13 (41.9) | 10 (32.3) | |||
Histologic type | |||||||
Ductal | 150 | 57 (38.0) | 0.142 | 49 (32.7) | 0.352 | 41 (27.3) | 0.313 |
Lobular | 6 | 2 (33.3) | 1 (16.7) | 2 (33.3) | |||
Mucinous | 3 | 1 (33.3) | 0 (0) | 2 (66.7) | |||
Lymph node metastasis | |||||||
0 | 55 | 9 (16.4) | 0.001 | 9 (16.4) | 0.006 | 15 (27.3) | 0.977 |
1 ~ 3 | 55 | 24 (43.6) | 19 (34.5) | 16 (29.1) | |||
>3 | 49 | 27 (55.1) | 22 (44.9) | 14 (28.6) | |||
Grade | |||||||
I | 13 | 6 (46.2) | 0.657 | 4 (30.8) | 0.906 | 4 (30.8) | 0.788 |
II | 102 | 36 (35.2) | 31 (30.4) | 27 (26.5) | |||
III | 44 | 18 (40.9) | 15 (34.1) | 14 (31.8) | |||
Stage | |||||||
I-II | 85 | 19 (22.4) | 0.001 | 19 (22.4) | 0.008 | 23 (27.1) | 0.709 |
III-IV | 74 | 41 (55.4) | 31 (41.9) | 22 (29.7) | |||
ER status^ | |||||||
- | 94 | 39 (41.5) | 0.24 | 27 (28.7) | 0.374 | 24 (25.5) | 0.351 |
+ | 65 | 21 (32.3) | 23 (35.4) | 21 (32.3) | |||
PR status^^ | |||||||
- | 90 | 32 (35.6) | 0.517 | 28 (31.1) | 0.917 | 22 (24.4) | 0.218 |
+ | 69 | 28 (40.6) | 22 (31.9) | 23 (33.3) | |||
HER-2 * | |||||||
- | 121 | 40 (33.1) | 0.03 | 31 (25.6) | 0.005 | 33 (27.3) | 0.607 |
+ | 38 | 20 (52.6) | 19 (50.0) | 12 (31.6) | |||